Clinical Trial

Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock

Study acronym: VASO-DIAG
Recruiting
View on ClinicalTrials.gov →
Summary
Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-25; most recent amendment 2026-01-06.
Status change: Active, Not Recruiting → Recruiting 2026-01-06
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-12-04
Trial Details
NCT Number NCT07203833
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Conditions Vasorin, Septic Shock, Shock, Biomarker, Infection
Enrollment 144 participants
Start Date 2025-10-19
Primary Completion 2027-04 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-07